Related Experiment Videos
Lens safety study with Picumast dihydrochloride--a double masked study using the Scheimpflug method
O Hockwin1, U Müller-Breitenkamp, H Laser
1Department of Experimental Ophthalmology, University of Bonn, F.R.G.
Lens and Eye Toxicity Research
|January 1, 1990
Summary
This study found no evidence that Picumast dihydrochloride, an antiallergic drug, harms human lens transparency. Ophthalmologic exams and Scheimpflug photography confirmed safety after one year of treatment.
Area of Science:
- Ophthalmology
- Pharmacology
- Drug Safety
Background:
- Antiallergic medications require thorough safety evaluations.
- Lens transparency is crucial for vision and can be affected by certain drugs.
Purpose of the Study:
- To investigate potential side effects of Picumast dihydrochloride on human lens transparency.
- To compare the effects of Picumast dihydrochloride and Ketotifen on ocular health.
Main Methods:
- A double-masked study involving 372 patients.
- Regular ophthalmologic examinations and Scheimpflug photography of the anterior eye segment.
- Microdensitometric analysis of film negatives after one year of treatment.
Main Results:
- No evidence of compromised lens transparency was found with Picumast dihydrochloride treatment.
- Slitlamp examinations and microdensitometric analyses confirmed the absence of negative effects on the lens.
- The study did not reveal any adverse impact on lens transparency in patients treated with Picumast dihydrochloride.
Conclusions:
- Picumast dihydrochloride does not appear to compromise lens transparency in humans.
- The antiallergic substance is deemed safe concerning lens opacity based on the study's findings.
- Further long-term studies may be warranted to confirm these safety findings.